Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)

Docket		Date Filed	2015-10-30
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To	Sherry R. Fallon
Parties	ACTAVIS INC.
Patents	8,454,996; 8,470,361; 8,658,198; 8,940,330; 9,259,421; 9,439,900
Attorneys	Jack B. Blumenfeld
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-30				External link to document
2015-10-30	14		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,658,198; 8,470,361; . (Phillips,…2015 10 January 2019 1:15-cv-00996 830 Patent Defendant District Court, D. Delaware	External link to document
2015-10-30	19		21, 2015. Date of Expiration of Patent: September 24, 2019 (8,454,996) and September 18, 2032 (8,940,330… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2015 10 January 2019 1:15-cv-00996 830 Patent Defendant District Court, D. Delaware	External link to document
2015-10-30	36		.I. 250 (D. Del. 2016) 4 U.S. Patent 8,454,996 5 U.S. Patent 8,940,330 6 Teva Pharmaceuticals…relating to the ’330 patent should be the same as in Zubsolv I relating to the ’330 patent.”); see also Orexo…Zubsolv I, II, III, and VIII, after patent expiration of the ’330 patent (2032) and enjoining Actavis from… ‘330 patent, the parties agree that Zubsolv IV-VII, and VIII as it relates to the ‘421 patent, should…stipulated judgements. 7 The patents at issue in Zubsolv IV-VII (U.S. Patents 9,259,421 and 9,439,900) expire	External link to document
2015-10-30	37		infringement of U.S. Patent Nos. 8,454,996 (“the ’996 patent”) and 8,940,330 (“the 330 patent’), based on the…of 7 PagelD #: 243 Patent Nos. 9,259,421 (“the ’421 patent”) and the ’330 patent, based on the filing… of the ’996 patent not invalid and infringed, and the asserted claims of the ’330 patent invalid; WHEREAS…complaints alleging infringement of the °996 patent and °330 patent, based on the filing by Actavis of ANDA…’996 patent are valid and Actavis’s ANDA 208450 infringes the asserted claims of the ’996 patent (C.A.	External link to document
2015-10-30	38		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,454,996 B2 ;8,940,330 B2. (…2015 10 January 2019 1:15-cv-00996 830 Patent Defendant District Court, D. Delaware	External link to document

Litigation summary and analysis for: Orexo AB v. Actavis Elizabeth LLC (D. Del. 2015)

Last updated: February 4, 2026

What Is the Litigation Involving Orexo AB v. Actavis Elizabeth LLC?

Orexo AB filed a patent infringement lawsuit against Actavis Elizabeth LLC (now part of Allergan, PLC) in the U.S. District Court for the District of Delaware (Case No. 1:15-cv-00996). The case centers on the alleged infringement of U.S. Patent No. 8,603,594, which covers formulations of buprenorphine. Orexo claims Actavis's proposed generic of its branded product, Suboxone Film, infringes on the patent. The litigation initiated in 2015, with the intent to prevent Actavis's entry into the market with its generic opioid addiction treatment.

What Are the Legal Claims and Patent Details?

Orexo's patent claims a specific sublingual film formulation, including an opioid antagonist and specific dosages designed to optimize delivery and bioavailability. The patent's primary claims focus on the composition and method of making the film.

The core legal allegation is that Actavis's generic violates the '594 patent’s claims by producing a bioequivalent formulation with similar compositions. Orexo seeks injunctive relief, damages from past infringement, and the prohibition of future sales of Actavis's generic.

What Was the Timeline and Key Procedural Events?

• 2015: Orexo filed suit against Actavis alleging patent infringement.

• 2016: Actavis filed a paragraph IV certification, challenging the patent's validity and asserting non-infringement, prompting Orange's patent infringement suit and triggering 30-month stay provisions under the Hatch-Waxman Act.

• 2017-2018: The case involved motions for summary judgment, patent claim construction, and validity challenges based on prior art.

• 2019: The parties settled the case before trial. The settlement terms were confidential, but typically such settlements involve licensing agreements or future market entry conditions.

What Are the Main Patent and Market Implications?

Orexo’s patent protects its franchise in the sublingual film space for opioid dependence, a significant market segment. The patent’s strength and validity directly influence the ability of generic manufacturers to enter the market with cheaper alternatives.

The case exhibits typical issues in pharmaceutical patent litigation: validity challenges based on anticipation or obviousness, claim construction disputes, and settlement strategies that influence market competition.

What Does the Settlement Mean for Market Competition?

While financial terms remain confidential, the outcome likely delayed Actavis’s generic launch for a period, preserving Orexo’s market exclusivity. The case exemplifies how patent litigation can serve as a strategic barrier to generic entry, influencing drug pricing and availability.

What Are the Broader Industry Trends Reflected in This Case?

This case emphasizes the prominence of sublingual film formulations in opioid addiction therapy. It underscores the ongoing patent disputes in the opioid and addiction treatment markets, driven by the lucrative nature of branded formulations and the challenges faced by generics regarding patent validity.

The litigation also illustrates the utilization of Paragraph IV certifications to challenge patents preemptively, a common practice in the pharmaceutical industry intended to expedite generic entry but often resulting in extended legal battles.

What Are the Risks for Stakeholders?

• For patent holders: The strength and robustness of the patent’s claims determine market exclusivity and licensing leverage.
• For generic manufacturers: Patent challenges can delay entry significantly and incur legal costs, but successful invalidation can open the market.
• For patients: Patent disputes can delay access to affordable generics, impacting drug prices and healthcare costs.
• For investors: Litigation outcomes influence stock prices for both patent holders and generic manufacturers; prolonged disputes create uncertainty.

Key Takeaways

• The Orexo AB v. Actavis Elizabeth LLC case illustrates the typical patent litigation process rooted in the Hatch-Waxman Act.
• Patent validity disputes focus heavily on claim construction and prior art considerations.
• Settlement often results in delayed generic entry, affecting pricing and market share.
• Patent strength in formulations like sublingual buprenorphine directly impacts revenue streams and market exclusivity.
• Industry trends point to continued legal conflicts over opioid addiction therapies amid high market valuation.

FAQs

Q1: How long do patent infringement litigations typically last in the pharmaceutical industry?
A: They span from 2 to 5 years, depending on complexity, appeal processes, and settlement negotiations.

Q2: What are the common defenses in patent infringement cases in pharma?
A: Defenses include patent invalidity claims based on anticipation, obviousness, or lack of novelty, along with non-infringement arguments.

Q3: How does the Paragraph IV certification influence patent litigation?
A: It triggers a 45-day period for patent holders to initiate infringement lawsuits, which can lead to a 30-month stay of FDA approval for the generic product.

Q4: What role does claim construction play in these cases?
A: It determines the scope of patent protections. Narrow claims can limit infringement, while broad claims can strengthen patent enforcement.

Q5: Are settlements common in pharmaceutical patent lawsuits?
A: Yes. Settlements often include licensing or delayed market entry, reducing litigation costs and uncertainty.

---

References:
[1] U.S. Patent No. 8,603,594.
[2] District of Delaware Litigation Docket (Case No. 1:15-cv-00996).
[3] FDA Hatch-Waxman Act provisions.